JP4925540B2 - ５−ヘリックスタンパク質 - Google Patents

５−ヘリックスタンパク質 Download PDF

Info

Publication number
JP4925540B2
JP4925540B2 JP2001544774A JP2001544774A JP4925540B2 JP 4925540 B2 JP4925540 B2 JP 4925540B2 JP 2001544774 A JP2001544774 A JP 2001544774A JP 2001544774 A JP2001544774 A JP 2001544774A JP 4925540 B2 JP4925540 B2 JP 4925540B2
Authority
JP
Japan
Prior art keywords
helix
hiv
protein
helices
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001544774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517006A (ja
JP2003517006A5 (enExample
Inventor
ルート，マイケル，ジェイ．
ケイ，マイケル，エス．
チャン，デービッド，シー．
キム，ピーター，エス．
Original Assignee
ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ filed Critical ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ
Publication of JP2003517006A publication Critical patent/JP2003517006A/ja
Publication of JP2003517006A5 publication Critical patent/JP2003517006A5/ja
Application granted granted Critical
Publication of JP4925540B2 publication Critical patent/JP4925540B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001544774A 1999-12-16 2000-12-15 ５−ヘリックスタンパク質 Expired - Fee Related JP4925540B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17104299P 1999-12-16 1999-12-16
US60/171,042 1999-12-16
US23457200P 2000-09-22 2000-09-22
US60/234,572 2000-09-22
PCT/US2000/034194 WO2001044286A2 (en) 1999-12-16 2000-12-15 Five-helix protein

Publications (3)

Publication Number Publication Date
JP2003517006A JP2003517006A (ja) 2003-05-20
JP2003517006A5 JP2003517006A5 (enExample) 2008-10-02
JP4925540B2 true JP4925540B2 (ja) 2012-04-25

Family

ID=26866680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544774A Expired - Fee Related JP4925540B2 (ja) 1999-12-16 2000-12-15 ５−ヘリックスタンパク質

Country Status (8)

Country Link
US (3) US7053179B2 (enExample)
EP (1) EP1237912B1 (enExample)
JP (1) JP4925540B2 (enExample)
AT (1) ATE380822T1 (enExample)
CA (1) CA2395291C (enExample)
DE (1) DE60037450T2 (enExample)
ES (1) ES2296665T3 (enExample)
WO (1) WO2001044286A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
JP2003529319A (ja) * 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
US7053179B2 (en) 1999-12-16 2006-05-30 Whitehead Institute For Biomedical Research Five-Helix protein
US6861253B2 (en) 2001-01-05 2005-03-01 Aventis Pasteur S.A. Polypeptide inducing antibodies neutralizing HIV
FR2819256B1 (fr) * 2001-01-05 2004-04-30 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
EP1390399B1 (en) 2001-05-31 2005-05-11 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
MXPA03011453A (es) 2001-06-15 2004-04-05 Hoffmann La Roche Acetilacion de fragmentos de gp41.
WO2003006056A2 (en) * 2001-07-11 2003-01-23 Genfa Zhou End-locked five-helix protein
CA2461853A1 (en) * 2001-09-27 2003-04-03 Tibotec Pharmaceuticals Ltd. Anti-fusion assay
ATE348888T1 (de) 2001-10-05 2007-01-15 Sanofi Pasteur Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
US20030219451A1 (en) * 2001-10-29 2003-11-27 Whitehead Institute For Biomedical Research Stable helical C peptides and uses therefor
FR2832715A1 (fr) * 2001-11-29 2003-05-30 Hippocampe Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7056519B2 (en) 2002-05-17 2006-06-06 Aventis Pasteur S.A. Methods for inducing HIV-neutralizing antibodies
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
WO2005018666A1 (en) * 2003-08-14 2005-03-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Polypeptide multimers having antiviral activity
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2005118886A2 (en) * 2004-06-01 2005-12-15 Merck & Co., Inc. Stable peptide mimetic of hiv gp41 fusion intermediate
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
RU2009137593A (ru) * 2007-03-12 2011-04-20 Томас Джефферсон Юниверсити (Us) Сильно связывающиеся с-пептидные ингибиторы проникновения вич-1 в клетку
ATE538129T1 (de) * 2007-09-07 2012-01-15 Complix N V Nicht natürliches proteinöses gerüst aus drei nicht kovalent assoziierten peptiden
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
GB2471692A (en) * 2009-07-08 2011-01-12 Complix Nv HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats
US9050063B2 (en) * 2012-03-30 2015-06-09 Sandance Technology Llc Systems and methods for determining suitability of a mechanical implant for a medical procedure
CN106946994B (zh) * 2017-03-09 2019-11-26 中国医学科学院病原生物学研究所 一种抑制丙型肝炎病毒感染的蛋白及其应用
CN110551179B (zh) * 2018-05-31 2022-03-15 中国科学院微生物研究所 一种经修饰的抗hiv多肽及其制备方法和用途
US20250298022A1 (en) 2022-05-03 2025-09-25 Roche Diagnostics Operations, Inc. Hiv gp41 variants for immunodiagnostic assays

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444044A (en) 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5780221A (en) 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
NZ311319A (en) 1995-06-07 2000-01-28 Trimeris Inc The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy
JP3903503B2 (ja) 1996-11-18 2007-04-11 住友電気工業株式会社 可溶性ポリペプチド
US6303317B1 (en) 1997-01-28 2001-10-16 The Regents Of The University Of California Peptide probes and methods for making the same
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6090911A (en) 1997-10-22 2000-07-18 University Of Massachusetts Reversible hydrogels
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP5101764B2 (ja) 1998-07-30 2012-12-19 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ膜融合のインヒビター
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) * 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
JP2003529319A (ja) * 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
US7053179B2 (en) 1999-12-16 2006-05-30 Whitehead Institute For Biomedical Research Five-Helix protein
US20030082525A1 (en) 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
CA2423004C (en) 2000-09-22 2012-09-11 Whitehead Institute For Biomedical Research Peptide inhibitors of hiv entry

Also Published As

Publication number Publication date
WO2001044286A3 (en) 2002-01-24
ES2296665T3 (es) 2008-05-01
EP1237912B1 (en) 2007-12-12
DE60037450T2 (de) 2008-12-04
JP2003517006A (ja) 2003-05-20
US7053179B2 (en) 2006-05-30
US7504224B2 (en) 2009-03-17
CA2395291C (en) 2012-09-11
DE60037450D1 (de) 2008-01-24
US20060014139A1 (en) 2006-01-19
EP1237912A2 (en) 2002-09-11
US20100196397A1 (en) 2010-08-05
US8058012B2 (en) 2011-11-15
WO2001044286A2 (en) 2001-06-21
CA2395291A1 (en) 2001-06-21
US20010047080A1 (en) 2001-11-29
ATE380822T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
JP4925540B2 (ja) ５−ヘリックスタンパク質
US7811578B2 (en) Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide
JP5788178B2 (ja) ウィルス感染症の治療のための組成物及び方法
US8372407B2 (en) Chimeric HIV fusion proteins as vaccines
US20030082525A1 (en) Five-Helix protein
EP2291392B1 (en) Bifunctional molecules for inhibiting hiv entry
AU2005225063B2 (en) Peptide inhibitors of HIV entry
US6080846A (en) Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus
AU2001292944A1 (en) Peptide inhibitors of HIV entry
US20080213292A1 (en) Soluble And Stabilized Trimeric Form Of Gp41 Polypeptides
CA2431881C (en) Polypeptide inducing hiv-neutralising antibodies
US20030219451A1 (en) Stable helical C peptides and uses therefor
Wang et al. Structural Basis of HIV-1 gp41 N-trimer for Designing Bifunctional Peptide-based Fusion Inhibitors
Sadler et al. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion‐active intermediate state
US6861253B2 (en) Polypeptide inducing antibodies neutralizing HIV
Quintana et al. Antibody response in rabbits against two HIV-1 multi-epitope polypeptides bearing different copies of V3 epitopes fused to the N terminal fragment of N. meningitidis P64K protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120207

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees